Quantcast
Last updated on April 16, 2014 at 5:20 EDT

Latest Cytomegalovirus Stories

2010-11-10 09:37:00

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2010 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the Lazard Capital Markets 7th Annual Healthcare Conference on Wednesday, November 17, 2010, 10:30 a.m. ET, at the St. Regis hotel in New York City. Mr. Moch will give an update on the company's pipeline and...

2010-11-09 12:08:00

AMSTERDAM, and RESEARCH TRIANGLE PARK, N.C., Nov. 9, 2010 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, announced that data supportive of the company's lead Phase 2 antiviral compound CMX001 were presented today during a late-breaker session by Hans H. Hirsch, MD, MSc, Professor of Clinical Virology, Division of Infectious Diseases, University of Basel, Switzerland, at the Antiviral Congress 2010 being held in Amsterdam, The...

2010-11-07 21:34:00

RESEARCH TRIANGLE PARK, N.C., Nov. 7, 2010 /PRNewswire-FirstCall/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today reaffirmed its commitment to the dual development of CMX001 as a medical countermeasure against smallpox and as a broad-spectrum antiviral agent. This statement follows notification from the Small Business Administration (SBA) that it has determined that SIGA Technologies, Inc. is not a small business, thus rendering SIGA...

2010-10-22 07:45:00

VANCOUVER, British Columbia and RESEARCH TRIANGLE PARK, N.C., Oct. 22 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, will present promising clinical data for CMX001 in a late-breaker poster session at the Infectious Diseases Society of America (IDSA) 48th Annual Meeting. Data from immunocompromised patients infected with adenovirus and treated with oral CMX001 demonstrated a significant drop in viral load compared to...

2010-10-12 13:51:51

More than 50% of adults in the United States test positive for human cytomegalovirus (HCMV) infection. For most people, infection produces no symptoms and results in the virus persisting in the body for a long time. HCMV infects many cell types in the body including the cells that line the intestines (IECs). New research, led by Sergio Lira, at Mount Sinai School of Medicine, New York, shows that mice engineered to express the HCMV protein US28 in IECs develop intestinal tumors as they age....

2010-09-28 10:51:00

RESEARCH TRIANGLE PARK, N.C., Sept. 28 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present a corporate overview at the upcoming BIO Investor Forum Conference on October 5th, 2010 at 2:00pm PT. The conference is being held at the Palace Hotel in San Francisco, California. Mr. Moch will discuss the company's antiviral pipeline and technology...

2010-09-28 08:42:00

MONMOUTH JUNCTION, N.J., Sept. 28 /PRNewswire/ -- Tamir Biotechnology, Inc. (Pink Sheets: ACEL) (formerly Alfacell Corporation) announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also...

2010-09-23 12:46:38

Researchers at IRB Barcelona have discovered this with the human cytomegalovirus, the most deadly and widespread herpesvirus and the cause of serious defects in neonates. Scientists at the Institute for Research in Biomedicine (IRB Barcelona) headed by the coordinator of the Structural and Computational Biology Programme, Miquel Coll, have published a new study that demonstrates that raltegravir, the drug approved in 2007 for the treatment of AIDS that is sold by Merck under the name...

2010-09-17 08:15:00

RESEARCH TRIANGLE PARK, N.C., Sept. 17 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present a corporate overview at the upcoming 12th Annual UBS Global Life Sciences Conference on September 22, 2010 at 3:30 pm ET. The conference is being held at the Grand Hyatt in New York City. Mr. Moch will discuss the company's antiviral pipeline and...

2010-09-15 12:22:00

Updated drug label will help prevent potential overdose in underweight transplant patients SILVER SPRING, Md., Sept. 15 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration is notifying health care professionals of updated dosing recommendations for Valcyte (valganciclovir) oral tablets and solution used by children and adolescents receiving a kidney or heart transplant. The update is intended to prevent drug overdosing of children with low body weight, low body surface area,...


Latest Cytomegalovirus Reference Libraries

0_bbd337098cfaf28eafeb5f5f010e48ef
2011-01-12 15:30:34

Cytomegalovirus, a herpes viral genus, is known in humans as HCMV. It is part of the Betaherpesvirinae subfamily. Other herpesviruses fall into the subfamilies of Alphaherpesvirinae or Gammaherpesvirinae. xHCMV infections are frequently associated with salivary glands. It can be lethal for people who are immunocompromised. Other CMV viruses are found in several mammal species, but species isolated from animals differ from HCMV in terms of genomic structure. HCMV is found all over the...

More Articles (1 articles) »